about
Rituximab for rheumatoid arthritisRituximab for rheumatoid arthritisThe emergence of proteinase-activated receptor-2 as a novel target for the treatment of inflammation-related CNS disordersEffect of adalimumab on neutrophil function in patients with rheumatoid arthritisPhase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomasStructural Plasticity of Malaria Dihydroorotate Dehydrogenase Allows Selective Binding of Diverse Chemical ScaffoldsRole of receptor tyrosine kinases in gastric cancer: new targets for a selective therapyGraves' ophthalmopathyHighly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapyHighly PEGylated DNA Nanoparticles Provide Uniform and Widespread Gene Transfer in the BrainSKLB023 blocks joint inflammation and cartilage destruction in arthritis models via suppression of nuclear factor-kappa B activation in macrophageComparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression AnalysisN-of-1 trials of expensive biological therapies: a third way?Extracellular TNFR1 release requires the calcium-dependent formation of a nucleobindin 2-ARTS-1 complex.Modulation of T cell function by combination of epitope specific and low dose anticytokine therapy controls autoimmune arthritis.Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety.Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice.Protective effect of geranylgeranylacetone, an inducer of heat shock protein 70, against drug-induced lung injury/fibrosis in an animal modelCheminformatics-aided discovery of small-molecule Protein-Protein Interaction (PPI) dual inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL).Anti‑inflammatory effects of oxymatrine on rheumatoid arthritis in rats via regulating the imbalance between Treg and Th17 cellsImaging of normal and pathologic joint synovium using nonlinear optical microscopy as a potential diagnostic tool.Plasmacytoid dendritic cell-derived IFN-α promotes murine liver ischemia/reperfusion injury by induction of hepatocyte IRF-1.Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy.A Case of Tumor Necrosis Factor-alpha Inhibitors-induced Pustular Psoriasis.The complex relationship between inflammation and lung function in severe asthmaSuppression of ongoing experimental arthritis by a chinese herbal formula (huo-luo-xiao-ling dan) involves changes in antigen-induced immunological and biochemical mediators of inflammation.Relationships between driving distance, rheumatoid arthritis diagnosis, and disease-modifying antirheumatic drug receipt.Biopharmaceuticals and monoclonal antibodies in oncology trials--a cross-sectional analysisCTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production.Cooperative role of tumour necrosis factor-α, interleukin-1β and neutrophils in a novel behavioural model that concomitantly demonstrates articular inflammation and hypernociception in mice.Immunomodulation of Autoimmune Arthritis by Herbal CAMSolid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort.CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathwayEffectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).Double-stranded RNA induces shedding of the 34-kDa soluble TNFR1 from human airway epithelial cells via TLR3-TRIF-RIP1-dependent signaling: roles for dual oxidase 2- and caspase-dependent pathways.Toll-like receptor, RIG-I-like receptors and the NLRP3 inflammasome: key modulators of innate immune responses to double-stranded RNA viruses.Randomised double-blind trial of combination antibiotic therapy in rheumatoid arthritis.The role of interleukin-1beta in direct and toll-like receptor 4-mediated neutrophil activation and survival.Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectivesA multicenter clinical trial in rheumatoid arthritis comparing silicone metacarpophalangeal joint arthroplasty with medical treatment.
P2860
Q24186568-705BB8B9-77E7-4CB2-B385-E6A593715776Q24242554-CEA6AFBE-71E4-4D74-968C-063A785440CBQ24679499-9B321042-0D66-499F-91AC-1C5EBBF6CD16Q24803670-DD521823-2751-4E9D-97BD-1F14465C9F04Q24813451-B81B1476-66DB-423E-A1A3-2CC04C3C143DQ27656755-20F882C5-8F23-4F4A-9E01-D52C6A155221Q28242840-F523EA4F-8E64-435E-B91B-A08487CCDCE9Q28274196-BD732B74-67EC-4391-BE62-386E2D6527ECQ28383844-A80EE82B-5AE6-43A6-BC42-643676AC4A7BQ28394137-A6D4A5F1-0500-4FF2-AF3F-ED7CB1F6F742Q28486238-DD397B55-1B3B-44C7-9661-41522BDE7691Q28547851-8CF3A7CE-20EE-4941-A7B3-2A9357648764Q30483827-14C00ABB-E883-472C-A5AE-4F13E6B29472Q33231442-4B6899E9-E62A-40D8-9DF2-489B90EA7AB1Q33267344-57C53750-98BB-4A08-AEFD-CE5984FCABC7Q33328963-DE42C24F-B1DF-468F-BE40-227388834B31Q33369142-C34F1D10-1A86-4007-A617-EC0D1F89B280Q33503888-B148E66B-644A-45C8-9C93-ABBFE5F5302AQ33584492-F525A134-EC15-47EC-9BE8-109F45E13CBDQ33702253-C46381D0-104E-4075-9A4E-9DC9D0760259Q33739631-25B5B35E-BF6C-4134-A5E1-6BA227884841Q33831458-063B7C1D-EDD7-40B4-978A-04E513A548F3Q33903812-D58D7DBF-D6BB-40DD-B830-82FFA5775AEEQ33904794-9DB72D8F-86AD-4722-BFA2-A21A2FAB45C2Q34067165-1B97CABB-3AD5-493A-BE35-F4C4E29D0DB6Q34219054-BD67D649-1DEF-4851-B423-20C8517278A4Q34244790-8EDC336C-2011-4250-A180-A79237E689B8Q34412989-764D52BB-2533-4D4D-8E2D-2054CFD21CD8Q34413292-3899AE86-C168-4371-9743-407069477EF7Q34449716-70A7FEB5-40F7-48FF-85F2-E83B701FEAEFQ34460609-00CDF8D4-47C3-404D-B884-88F848A2A153Q34628409-C9D80D86-A110-46D7-A6FE-8CE7CF8D5796Q34652416-D421170F-390E-445E-9E50-F43B76DDC7B1Q34758824-C45823BD-7B41-4A31-A3B4-90C044C38BB7Q34788072-879B07E8-A4BA-41E0-9866-853B10E6CCB4Q35028032-03CDA187-0DE4-4590-9BD1-EEC85F139B22Q35098842-A514ED08-6695-4018-97D5-98E158CF0793Q35103433-21377D95-9653-4642-BC72-417E43B16FD0Q35133812-BE776DB1-90A1-4B26-9B1B-54479C6C639FQ35240630-58E869BD-3805-4762-A80B-F7F251F1D388
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
New drugs for rheumatoid arthritis.
@ast
New drugs for rheumatoid arthritis.
@en
type
label
New drugs for rheumatoid arthritis.
@ast
New drugs for rheumatoid arthritis.
@en
prefLabel
New drugs for rheumatoid arthritis.
@ast
New drugs for rheumatoid arthritis.
@en
P356
P1476
New drugs for rheumatoid arthritis.
@en
P2093
C Michael Stein
Nancy J Olsen
P304
P356
10.1056/NEJMRA032906
P407
P577
2004-05-01T00:00:00Z